NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies

Nicolaus Kröger, Ulrike Bacher, Peter Bader, Sebastian Böttcher, Michael J. Borowitz, Peter Dreger, Issa Khouri, Eduardo Olavarria, Jerald Radich, Wendy Stock, Julie Marie Vose, Daniel Weisdorf, Andre Willasch, Sergio Giralt, Michael R. Bishop, Alan S. Wayne

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescence in situ hybridization (FISH), and multiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell transplantation to monitor patients, but not all of them are included in the commonly employed disease-specific response criteria. The highest sensitivity and specificity can be achieved by molecular monitoring of tumor- or patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have such targets for monitoring. Similar high sensitivity can be achieved by determination of recipient-donor chimerism, but its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summarize the current knowledge about the utilization of such sensitive monitoring techniques in chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies based on tumor-specific markers and cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically important is the need for standardization of the different residual disease techniques and to assess the clinical relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn must be followed by studies to assess the potential impact of specific interventional strategies.

Original languageEnglish (US)
Pages (from-to)1325-1346
Number of pages22
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2010

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Secondary Prevention
Leukemia
Education
Recurrence
Chimerism
Neoplasms
Residual Neoplasm
Therapeutics
Hematologic Neoplasms
Tumor Biomarkers
Treatment Failure
Fluorescence In Situ Hybridization
Molecular Biology
Flow Cytometry
Transplantation
Tissue Donors
Sensitivity and Specificity
Polymerase Chain Reaction

Keywords

  • Allogeneic stem cell transplantation
  • Chimerism
  • Chronic leukemias
  • Minimal residual disease
  • Myeloproliferative neoplasms, and lymphoid malignancies

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation : Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. / Kröger, Nicolaus; Bacher, Ulrike; Bader, Peter; Böttcher, Sebastian; Borowitz, Michael J.; Dreger, Peter; Khouri, Issa; Olavarria, Eduardo; Radich, Jerald; Stock, Wendy; Vose, Julie Marie; Weisdorf, Daniel; Willasch, Andre; Giralt, Sergio; Bishop, Michael R.; Wayne, Alan S.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 10, 01.10.2010, p. 1325-1346.

Research output: Contribution to journalArticle

Kröger, Nicolaus ; Bacher, Ulrike ; Bader, Peter ; Böttcher, Sebastian ; Borowitz, Michael J. ; Dreger, Peter ; Khouri, Issa ; Olavarria, Eduardo ; Radich, Jerald ; Stock, Wendy ; Vose, Julie Marie ; Weisdorf, Daniel ; Willasch, Andre ; Giralt, Sergio ; Bishop, Michael R. ; Wayne, Alan S. / NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation : Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 10. pp. 1325-1346.
@article{20b73b22de524b3f966fe5b16172e9a0,
title = "NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies",
abstract = "Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescence in situ hybridization (FISH), and multiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell transplantation to monitor patients, but not all of them are included in the commonly employed disease-specific response criteria. The highest sensitivity and specificity can be achieved by molecular monitoring of tumor- or patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have such targets for monitoring. Similar high sensitivity can be achieved by determination of recipient-donor chimerism, but its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summarize the current knowledge about the utilization of such sensitive monitoring techniques in chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies based on tumor-specific markers and cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically important is the need for standardization of the different residual disease techniques and to assess the clinical relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn must be followed by studies to assess the potential impact of specific interventional strategies.",
keywords = "Allogeneic stem cell transplantation, Chimerism, Chronic leukemias, Minimal residual disease, Myeloproliferative neoplasms, and lymphoid malignancies",
author = "Nicolaus Kr{\"o}ger and Ulrike Bacher and Peter Bader and Sebastian B{\"o}ttcher and Borowitz, {Michael J.} and Peter Dreger and Issa Khouri and Eduardo Olavarria and Jerald Radich and Wendy Stock and Vose, {Julie Marie} and Daniel Weisdorf and Andre Willasch and Sergio Giralt and Bishop, {Michael R.} and Wayne, {Alan S.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.bbmt.2010.07.001",
language = "English (US)",
volume = "16",
pages = "1325--1346",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation

T2 - Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies

AU - Kröger, Nicolaus

AU - Bacher, Ulrike

AU - Bader, Peter

AU - Böttcher, Sebastian

AU - Borowitz, Michael J.

AU - Dreger, Peter

AU - Khouri, Issa

AU - Olavarria, Eduardo

AU - Radich, Jerald

AU - Stock, Wendy

AU - Vose, Julie Marie

AU - Weisdorf, Daniel

AU - Willasch, Andre

AU - Giralt, Sergio

AU - Bishop, Michael R.

AU - Wayne, Alan S.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescence in situ hybridization (FISH), and multiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell transplantation to monitor patients, but not all of them are included in the commonly employed disease-specific response criteria. The highest sensitivity and specificity can be achieved by molecular monitoring of tumor- or patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have such targets for monitoring. Similar high sensitivity can be achieved by determination of recipient-donor chimerism, but its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summarize the current knowledge about the utilization of such sensitive monitoring techniques in chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies based on tumor-specific markers and cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically important is the need for standardization of the different residual disease techniques and to assess the clinical relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn must be followed by studies to assess the potential impact of specific interventional strategies.

AB - Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescence in situ hybridization (FISH), and multiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell transplantation to monitor patients, but not all of them are included in the commonly employed disease-specific response criteria. The highest sensitivity and specificity can be achieved by molecular monitoring of tumor- or patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have such targets for monitoring. Similar high sensitivity can be achieved by determination of recipient-donor chimerism, but its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summarize the current knowledge about the utilization of such sensitive monitoring techniques in chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies based on tumor-specific markers and cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically important is the need for standardization of the different residual disease techniques and to assess the clinical relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn must be followed by studies to assess the potential impact of specific interventional strategies.

KW - Allogeneic stem cell transplantation

KW - Chimerism

KW - Chronic leukemias

KW - Minimal residual disease

KW - Myeloproliferative neoplasms, and lymphoid malignancies

UR - http://www.scopus.com/inward/record.url?scp=77956309607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956309607&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.07.001

DO - 10.1016/j.bbmt.2010.07.001

M3 - Article

C2 - 20637879

AN - SCOPUS:77956309607

VL - 16

SP - 1325

EP - 1346

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -